UniQure has announced plans to submit its groundbreaking Huntington’s disease gene therapy, AMT-130, for regulatory approval in the United Kingdom later this year, marking a significant step forward for the company following a disappointing reversal by the U.S. Food and Drug Administration.

The Therapy and Its Promise

AMT-130 represents one of the most advanced treatments currently in development for Huntington’s disease, a progressive neurodegenerative condition that affects nerve function and currently has no cure. The therapy works by silencing a gene responsible for producing a mutated protein linked to nerve damage. According to PharmaDive.com, UniQure’s approach targets the root cause of the disease rather than merely managing its symptoms, as current treatments do.

UK Approval and Regulatory Path

The company’s decision to pursue UK approval comes after a positive meeting with British drug regulators, positioning AMT-130 for submission based on three-year analysis data from ongoing trials in the United States and Europe. This data demonstrates an apparent slowing of disease progression at the highest dose tested, encouraging results that form the foundation of the UK application.

CEO Matt Kapusta emphasized the company’s commitment to the Huntington’s community, stating that UniQure remains dedicated to working with regulators globally to bring the therapy to patients.

US Regulatory Challenges

The UK submission represents a potential turning point for UniQure after facing significant hurdles in the U.S. The FDA recently demanded that the company conduct an entirely new “sham-controlled” trial before considering approval, a requirement that industry analysts described as a “worst-case scenario.” This decision surprised UniQure, which had claimed the FDA’s position represented a shift from previously positive feedback.

The conflict escalated into a public dispute between the company and the FDA, reflecting broader tensions between the agency and developers of rare disease treatments seeking approval under expedited pathways.

Moving Forward on Multiple Fronts

Despite U.S. challenges, UniQure continues engagement with American regulators. A critical meeting with the FDA is scheduled for the second quarter, where both parties will discuss key elements of a potential new Phase 3 trial design. Additionally, the FDA will provide feedback on a four-year study analysis expected in the third quarter. The company plans to provide updates on approval strategies in other countries as well.